Advances in using PARP inhibitors to treat cancer

Shivaani Kummar, Alice Chen, Ralph E. Parchment, Robert J. Kinders, Jay Ji, Joseph E. Tomaszewski, James H. Doroshow

Research output: Contribution to journalShort surveypeer-review

24 Scopus citations


The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a critical role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair. PARP1 is overexpressed in a variety of cancers, and its expression has been associated with overall prognosis in cancer, especially breast cancer. A series of new therapeutic agents that are potent inhibitors of the PARP1 and PARP2 isoforms have demonstrated important clinical activity in patients with breast or ovarian cancers that are caused by mutations in either the BRCA1 or 2 genes. Results from such studies may define a new therapeutic paradigm, wherein simultaneous loss of the capacity to repair DNA damage may have antitumor activity in itself, as well as enhance the antineoplastic potential of cytotoxic chemotherapeutic agents.

Original languageEnglish (US)
Article number25
JournalBMC Medicine
StatePublished - Mar 9 2012
Externally publishedYes


  • DNA repair
  • PARP clinical trials
  • Synthetic lethality

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Advances in using PARP inhibitors to treat cancer'. Together they form a unique fingerprint.

Cite this